Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Kaiser Permanente
Duke University
Arvinas Inc.
ALX Oncology Inc.
University of Colorado, Denver
City of Hope Medical Center
Seagen Inc.
Eli Lilly and Company
Novartis
National Institutes of Health Clinical Center (CC)
Var2 Pharmaceuticals
Takeda
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
Centre for Research and Technology Hellas
Turning Point Therapeutics, Inc.
Apollomics Inc.
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Hoffmann-La Roche
Compugen Ltd
Columbia University
Vyriad, Inc.
Intensity Therapeutics, Inc.
Cyprus University of Technology
PureTech
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
NextCure, Inc.
Washington University School of Medicine
European Organisation for Research and Treatment of Cancer - EORTC
NantCell, Inc.
Washington University School of Medicine
HiberCell, Inc.
Klus Pharma Inc.
Kineta Inc.
Eastern Cooperative Oncology Group
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Icahn School of Medicine at Mount Sinai
Roswell Park Cancer Institute
MacroGenics
MacroGenics
Federal University of Minas Gerais
Institut Bergonié